DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Aducanumab
Aducanumab
Letter to FDA on Review of Biogen's Drug
Refreshing the Biologic Pipeline 2020
Horizon Scanning Status Report June 2019
Treatment of Alzheimer's Disease and Blood–Brain Barrier Drug Delivery
Medical Drug and Step Therapy Prior Authorization List for Medicare Plus Bluesm and BCN Advantagesm Members Revised September 2021
Tables-Of-Phase-3-Mabs.Pdf
The Two Tontti Tudiul Lui Hi Ha Unit
Antibodies to Watch in 2021 Hélène Kaplona and Janice M
Review at Launch Medication List
(12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
Monoclonal Antibodies As Neurological Therapeutics
Lääkeaineiden Yleisnimet (INN-Nimet) 21.6.2021
Rxoutlook® 4Th Quarter 2020
Aducanumab for Alzheimer's Disease
Minutes of the CHMP Meeting 9-12 November 2020
Outlook for Global Medicines Through 2021 Balancing Cost and Value
Aducanumab-Avwa (Aduhelm™) Restricted Product(S)
PCORI-HCHSS-High Potential Disruption-May-2021
Top View
Novel Amyloid Beta Monoclonal Antibodies with Superior Binding
What Have We Learned from Aducanumab?
Three Essays in Health Economics
Horizon Scanning Status Report December 2020
Review at Launch Medication List
INSIGHTS Newsletter Issue 26 | June 2021
PCORI High Potential Disruption Report, November 2020
(INN) for Biological and Biotechnological Substances
Medical Benefit Injectable Drugs | Kaiser Permanente Washington
OCTOBER 2019 Mrx Pipeline a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
Rxoutlook® 3Rd Quarter 2020
Specialty Pipeline MONTHLY UPDATE
Aducanumab Produced a Clinically Meaningful Benefit in Association
A Rationally Designed Humanized Antibody Selective for Amyloid Beta
(CHMP) Agenda for the Meeting on 21-24 June 2021
Labeling: • Amyloid Related Imaging Abnormalities [See Warnings and Precautions (5.1)] • Hypersensitivity Reactions [See Warnings and Precautions (5.2)]
Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks
Aducanumab for Alzheimer's Disease?
A View Into Upcoming Specialty & Traditional Drugs
Rxoutlook® 2Nd Quarter 2021
Why Aducanumab Failure Is Not the End of Amyloid Hypothesis
Minutes of the CHMP Meeting 22-25 February 2021
ATC/DDD Classification (Temporary)
Biogen Files New Drug Application for Aducanumab in Japan
Procedures, Programs, and Drugs That Require Precertification
Biogen Inc. 2020 Annual Report
Fecal Microbiota Potentiate Checkpoint Inhibitors, Unleash Microbiome
EMERGE and ENGAGE Topline Results: Two Phase 3 Studies to Evaluate Aducanumab in Patients with Early Alzheimer’S Disease
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer’S Disease and Dementia at the 13Th Clinical Trials on Alzheimer’S Disease Conference
(INN) for Biological and Biotechnological Substances
Aducanumab Titration Dosing Regimen
(INN-Nimet) 15.6.2020
Specialty Pipeline MONTHLY UPDATE
Thesis (PDF, 14.95MB)
An About Face As Biogen Says It Will File Aducanumab in Alzheimer's
A Comparative Study of the Effects of Aducanumab and Scanning Ultrasound
Review at Launch Medication List (For Indiana Only)
NH Healthy Families Pharmacy & Therapeutics Committee 21Q2
WO 2016/059622 A2 21 April 2016 (21.04.2016) P O P C T
Medication Administration Site of Care
Aducanumab for the Treatment of Alzheimer's Disease US Food
CHMP Agenda of the 19-22 July 2021 Meeting